Cargando…

Fatty acid amide hydrolase inhibition and N‐arachidonoylethanolamine modulation by isoflavonoids: A novel target for upcoming antidepressants

Modulation of the endocannabinoid system (ECS) is a novel putative target for therapeutic intervention in depressive disorders. Altering concentrations of one of the principal endocannabinoids, N‐arachidonoylethanolamine, also known as anandamide (AEA) can affect depressive‐like behaviors through se...

Descripción completa

Detalles Bibliográficos
Autores principales: Zada, Wahid, VanRyzin, Jonathan W., Perez‐Pouchoulen, Miguel, Baglot, Samantha L., Hill, Matthew N., Abbas, Ghulam, Clark, Sarah M., Rashid, Umer, McCarthy, Margaret M., Mannan, Abdul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418665/
https://www.ncbi.nlm.nih.gov/pubmed/36029006
http://dx.doi.org/10.1002/prp2.999
_version_ 1784776999220281344
author Zada, Wahid
VanRyzin, Jonathan W.
Perez‐Pouchoulen, Miguel
Baglot, Samantha L.
Hill, Matthew N.
Abbas, Ghulam
Clark, Sarah M.
Rashid, Umer
McCarthy, Margaret M.
Mannan, Abdul
author_facet Zada, Wahid
VanRyzin, Jonathan W.
Perez‐Pouchoulen, Miguel
Baglot, Samantha L.
Hill, Matthew N.
Abbas, Ghulam
Clark, Sarah M.
Rashid, Umer
McCarthy, Margaret M.
Mannan, Abdul
author_sort Zada, Wahid
collection PubMed
description Modulation of the endocannabinoid system (ECS) is a novel putative target for therapeutic intervention in depressive disorders. Altering concentrations of one of the principal endocannabinoids, N‐arachidonoylethanolamine, also known as anandamide (AEA) can affect depressive‐like behaviors through several mechanisms including anti‐inflammatory, hormonal, and neural circuit alterations. Recently, isoflavonoids, a class of plant‐derived compounds, have been of therapeutic interest given their ability to modulate the metabolism of the endogenous ligands of the ECS. To determine the therapeutic potential of isoflavonoids, we screened several candidate compounds (Genistein, Biochanin‐A, and 7‐hydroxyflavone) in silico to determine their binding properties with fatty acid amide hydrolase (FAAH), the primary degrative enzyme for AEA. We further validated the ability of these compounds to inhibit FAAH and determined their effects on depressive‐like and locomotor behaviors in the forced swim test (FST) and open field test in male and female mice. We found that while genistein was the most potent FAAH inhibitor, 7‐hydroxyflavone was most effective at reducing immobility time in the forced swim test. Finally, we measured blood corticosterone and prefrontal cortex AEA concentrations following the forced swim test and found that all tested compounds decreased corticosterone and increased AEA, demonstrating that isoflavonoids are promising therapeutic targets as FAAH inhibitors.
format Online
Article
Text
id pubmed-9418665
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-94186652022-08-31 Fatty acid amide hydrolase inhibition and N‐arachidonoylethanolamine modulation by isoflavonoids: A novel target for upcoming antidepressants Zada, Wahid VanRyzin, Jonathan W. Perez‐Pouchoulen, Miguel Baglot, Samantha L. Hill, Matthew N. Abbas, Ghulam Clark, Sarah M. Rashid, Umer McCarthy, Margaret M. Mannan, Abdul Pharmacol Res Perspect Original Articles Modulation of the endocannabinoid system (ECS) is a novel putative target for therapeutic intervention in depressive disorders. Altering concentrations of one of the principal endocannabinoids, N‐arachidonoylethanolamine, also known as anandamide (AEA) can affect depressive‐like behaviors through several mechanisms including anti‐inflammatory, hormonal, and neural circuit alterations. Recently, isoflavonoids, a class of plant‐derived compounds, have been of therapeutic interest given their ability to modulate the metabolism of the endogenous ligands of the ECS. To determine the therapeutic potential of isoflavonoids, we screened several candidate compounds (Genistein, Biochanin‐A, and 7‐hydroxyflavone) in silico to determine their binding properties with fatty acid amide hydrolase (FAAH), the primary degrative enzyme for AEA. We further validated the ability of these compounds to inhibit FAAH and determined their effects on depressive‐like and locomotor behaviors in the forced swim test (FST) and open field test in male and female mice. We found that while genistein was the most potent FAAH inhibitor, 7‐hydroxyflavone was most effective at reducing immobility time in the forced swim test. Finally, we measured blood corticosterone and prefrontal cortex AEA concentrations following the forced swim test and found that all tested compounds decreased corticosterone and increased AEA, demonstrating that isoflavonoids are promising therapeutic targets as FAAH inhibitors. John Wiley and Sons Inc. 2022-08-26 /pmc/articles/PMC9418665/ /pubmed/36029006 http://dx.doi.org/10.1002/prp2.999 Text en © 2022 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Zada, Wahid
VanRyzin, Jonathan W.
Perez‐Pouchoulen, Miguel
Baglot, Samantha L.
Hill, Matthew N.
Abbas, Ghulam
Clark, Sarah M.
Rashid, Umer
McCarthy, Margaret M.
Mannan, Abdul
Fatty acid amide hydrolase inhibition and N‐arachidonoylethanolamine modulation by isoflavonoids: A novel target for upcoming antidepressants
title Fatty acid amide hydrolase inhibition and N‐arachidonoylethanolamine modulation by isoflavonoids: A novel target for upcoming antidepressants
title_full Fatty acid amide hydrolase inhibition and N‐arachidonoylethanolamine modulation by isoflavonoids: A novel target for upcoming antidepressants
title_fullStr Fatty acid amide hydrolase inhibition and N‐arachidonoylethanolamine modulation by isoflavonoids: A novel target for upcoming antidepressants
title_full_unstemmed Fatty acid amide hydrolase inhibition and N‐arachidonoylethanolamine modulation by isoflavonoids: A novel target for upcoming antidepressants
title_short Fatty acid amide hydrolase inhibition and N‐arachidonoylethanolamine modulation by isoflavonoids: A novel target for upcoming antidepressants
title_sort fatty acid amide hydrolase inhibition and n‐arachidonoylethanolamine modulation by isoflavonoids: a novel target for upcoming antidepressants
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418665/
https://www.ncbi.nlm.nih.gov/pubmed/36029006
http://dx.doi.org/10.1002/prp2.999
work_keys_str_mv AT zadawahid fattyacidamidehydrolaseinhibitionandnarachidonoylethanolaminemodulationbyisoflavonoidsanoveltargetforupcomingantidepressants
AT vanryzinjonathanw fattyacidamidehydrolaseinhibitionandnarachidonoylethanolaminemodulationbyisoflavonoidsanoveltargetforupcomingantidepressants
AT perezpouchoulenmiguel fattyacidamidehydrolaseinhibitionandnarachidonoylethanolaminemodulationbyisoflavonoidsanoveltargetforupcomingantidepressants
AT baglotsamanthal fattyacidamidehydrolaseinhibitionandnarachidonoylethanolaminemodulationbyisoflavonoidsanoveltargetforupcomingantidepressants
AT hillmatthewn fattyacidamidehydrolaseinhibitionandnarachidonoylethanolaminemodulationbyisoflavonoidsanoveltargetforupcomingantidepressants
AT abbasghulam fattyacidamidehydrolaseinhibitionandnarachidonoylethanolaminemodulationbyisoflavonoidsanoveltargetforupcomingantidepressants
AT clarksarahm fattyacidamidehydrolaseinhibitionandnarachidonoylethanolaminemodulationbyisoflavonoidsanoveltargetforupcomingantidepressants
AT rashidumer fattyacidamidehydrolaseinhibitionandnarachidonoylethanolaminemodulationbyisoflavonoidsanoveltargetforupcomingantidepressants
AT mccarthymargaretm fattyacidamidehydrolaseinhibitionandnarachidonoylethanolaminemodulationbyisoflavonoidsanoveltargetforupcomingantidepressants
AT mannanabdul fattyacidamidehydrolaseinhibitionandnarachidonoylethanolaminemodulationbyisoflavonoidsanoveltargetforupcomingantidepressants